中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
In-situ vaccination immunotherapy of colorectal cancer with STING agonist-integrated supramolecular nanovectors

文献类型：期刊论文

作者Liu, Xiaoying6,7,8; Chen, Fangmin5,6,7; Saeed, Madiha4,6,7; Li, Xutong4; Zhang, Huijuan6,7; Zhang, Jiangying2; Zheng, Mingyue3; Wang, Feng8; Wang, Hui1; Yu, Haijun5,6,7
刊名NANO TODAY
出版日期2024-06-01
卷号56页码:13
关键词Supramolecular nanovector STING activation Colorectal cancer In -situ vaccination Cancer immunotherapy
ISSN号1748-0132
DOI10.1016/j.nantod.2024.102273
通讯作者Wang, Feng(prof.fengwang@tongji.edu.cn) ; Wang, Hui(cewangh@imu.edu.cn) ; Yu, Haijun(hjyu@simm.ac.cn)
英文摘要The immunosuppressive tumor immune microenvironment and low tumor immunogenicity invariably subvert the efficacy of cancer vaccine and the antitumor immunity. An alternative approach to improve cancer vaccination immunotherapy is to synergistically trigger stimulator of interferon genes (STING) activation for transforming immunologically 'cold ' tumor into 'hot ' tumor. Herein, we presented a supramolecular nanovector (namely HCCSM) integrating with the chemotherapeutic agent camptothecin (CPT) and STING agonist MSA-2 for in -situ vaccination immunotherapy of colorectal cancer. The nanovector was prepared via well-tunable hostguest complexation of cyclodextrin-grafted hyaluronic acid with MSA-2 and adamantine-conjugated prodrug of CPT. Upon intravenous injection, HCCSM achieved active tumor targeting by recognizing highly expressed CD44 on colorectal tumor cells, and specifically co-delivered CPT and MSA-2 into tumors. CPT effectively induced immunogenic cell death (ICD) of tumor cells and triggered tumor-associated antigens (TAAs) release at the tumor site. Subsequently, tumor infiltrating-dendritic cells captured TAAs and MSA-2 to enhance antigen crosspresentation through the activation of STING pathway and secretion of type-I interferon. HCCSM elicited robust antitumor immunity and thus exhibited remarkable therapeutic benefit in primary and distant CT26 colorectal tumors. Our developed nanovector represents an effective combination strategy for vaccination immunotherapy of colorectal cancer.
资助项目National Facility for Protein Science in Shanghai (NFPS) , Shanghai Advanced Research Institute, CAS ; Shanghai Institute of Materia Medica, CAS
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science
语种英语
WOS记录号WOS:001234968100001
出版者ELSEVIER SCI LTD
源URL[http://119.78.100.183/handle/2S10ELR8/311755]  
专题新药研究国家重点实验室
通讯作者Wang, Feng; Wang, Hui; Yu, Haijun
作者单位1.Inner Mongolia Univ, Coll Chem & Chem Engn, Inner Mongolia 010021, Peoples R China
2.lnner Mongolia Peoples Hosp, Hohhot 010000, Peoples R China
3.Chinese Acad Sci, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
4.COMSATS Univ Islamabad, Interdisciplinary Res Ctr Biomed Mat, Lahore Campus, Lahore 54000, Pakistan
5.Univ Chinese Acad Sci, Beijing 100049, Peoples R China
6.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China
7.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Chem Biol, Shanghai 201203, Peoples R China
8.Fudan Univ, Huadong Hosp, Shanghai Med Coll, Dept Gastroenterol, Shanghai 200040, Peoples R China
推荐引用方式
GB/T 7714		 Liu, Xiaoying,Chen, Fangmin,Saeed, Madiha,et al. In-situ vaccination immunotherapy of colorectal cancer with STING agonist-integrated supramolecular nanovectors[J]. NANO TODAY,2024,56:13.
APA Liu, Xiaoying.,Chen, Fangmin.,Saeed, Madiha.,Li, Xutong.,Zhang, Huijuan.,...&Yu, Haijun.(2024).In-situ vaccination immunotherapy of colorectal cancer with STING agonist-integrated supramolecular nanovectors.NANO TODAY,56,13.
MLA Liu, Xiaoying,et al."In-situ vaccination immunotherapy of colorectal cancer with STING agonist-integrated supramolecular nanovectors".NANO TODAY 56(2024):13.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。